Vorapaxar is a tricyclic himbacine-derived selective inhibitor of the protease-activated receptor-1 (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history… Read more
Vorapaxar is a tricyclic himbacine-derived selective inhibitor of the protease-activated receptor-1 (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction or peripheral arterial disease. This category contains high-quality reference standards of the Vorapaxar active pharmaceutical ingredient, its sulfate salt form, associated impurities, and stable isotope labelled compounds. Pharmaceutical and analytical laboratories utilize these materials for impurity profiling, method validation, and rigorous quality control testing. By providing reliable standards for mass spectrometry quantification and chromatographic analysis, these compounds ensure precision and regulatory compliance during the development of drug products and stability studies. Researchers can access these essential tools to support comprehensive analytical workflows and ensure the accuracy of identification and quantitation processes in cardiovascular drug development.